Fosun Pharma (02696): The international multicenter phase I clinical study of the biosimilar drug HLX17 of Palbociclib monoclonal antibody has been completed in patients with various resected solid tumors, with the first American patient being dosed.

China Fortune Financial News APP News, Fosun Pharma (02696) announced that recently, the international multicenter phase 1 clinical study of the company's independently developed Paboliuzhu monoclonal antibody biosimilar HLX17 (recombinant anti-PD-1 humanized monoclonal antibody injection) (HLX17) in patients with various resected solid tumors has completed the first dosing of a patient in the United States. The phase 1 clinical study is also being conducted simultaneously in China (excluding mainland China, Hong Kong, Macao and Taiwan).